Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia

被引:41
|
作者
Koziel, H
Kim, S
Reardon, C
Li, XH
Garland, R
Pinkston, P
Kornfeld, H
机构
[1] Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Dept Med, Boston, MA 02215 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Boston Univ, Sch Med, Boston, MA 02118 USA
[4] Boston Med Ctr, Div Pulm & Crit Care, Boston, MA USA
关键词
D O I
10.1164/ajrccm.160.6.9902099
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
The relationship of serum human immunodeficiency virus-1 (HIV-1) RNA levels to HIV-1 RNA levels in other compartments, such as the lungs, is not well characterized. The purpose of this study was to determine the viral burden of HIV-1 in the lungs by comparing HIV-1 RNA in cell-free bronchoalveolar lavage fluid (BALF) with that in serum. Specimens were examined from 77 HIV-seropositive adults (CD4(+) cell counts: 0 to 700 cells/mm(3); 48% receiving prescribed antiretroviral agents), comprising 43 asymptomatic individuals who were compared with 34 persons with active lung disease caused by Pneumocystis carinii (n = 26), bacteria (n = 3), Mycobacterium avium complex (n = 2), Nocardia sp. (n = 1), Aspergillus sp. (n = 1), or pulmonary Kaposi's sarcoma (n = 1). For serum HIV-1 RNA, the proportion of subjects with detectable levels and the mean values were similar for asymptomatic individuals and persons with active lung disease (85% versus 86%, respectively) (6.64 x 10(4) versus 1.81 x 10(5) HIV-1 RNA copies/ml; p = 0.13). In contrast, HIV-1 RNA in BALF was more often detected (16% versus 62%; p = 0.001), and mean values were higher(1.04 x 10(5) versus 3.31 x 10(6) HIV-1 RNA copies/ml; p = 0.032), in subjects with active lung disease than in asymptomatic subjects, independent of early or advanced clinical stages of HIV-related disease. For both study groups, HIV-l RNA levels in BALF exceeded those in serum in 56% of cases by up to 66-fold, and did not correlate with local levels of tumor necrosis factor-alpha granulocyte-macrophage colony-stimulating factor, or interleukin-16. HIV-1 proviral DNA in cells from BALF was detected in up to 86% of subjects, more frequently in persons with advanced HIV disease (p = 0.0496), and often involved > 10% of BALF cells, but did not correlate with HIV-1 RNA detected in BALF. These data provide evidence for active HIV-1 replication in the lungs. HIV-1 replication is compartmentalized relative to serum, may be restricted, is independent of HIV-1 proviral DNA and clinical stage of HIV, and may be influenced by pulmonary disease such as P. carinii pneumonia or by other local or lung-specific factors. The lungs represent a large reservoir for HIV-1, and may present a source of persistent HIV-1 replication even during periods of apparent clinical latency of HIV-1 infection.
引用
收藏
页码:2048 / 2055
页数:8
相关论文
共 50 条
  • [21] RESPIRATORY SYNCYTIAL VIRUS PNEUMONIA IN A HUMAN IMMUNODEFICIENCY VIRUS-INFECTED MAN
    MURPHY, D
    ROSE, RC
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1989, 261 (08): : 1147 - 1147
  • [22] THE RISK OF PNEUMOCYSTIS-CARINII PNEUMONIA AMONG MEN INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS TYPE-1
    PHAIR, J
    MUNOZ, A
    DETELS, R
    KASLOW, R
    RINALDO, C
    SAAH, A
    NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (03): : 161 - 165
  • [23] PNEUMOCYSTIS-CARINII PNEUMONIA IN A HUMAN-IMMUNODEFICIENCY-VIRUS 1-INFECTED NEONATE WITH MECONIUM ASPIRATION
    BEACH, RS
    GARCIA, ER
    SOSA, R
    GOOD, RA
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1991, 10 (12) : 953 - 955
  • [24] Impact of bacterial pneumonia and Pneumocystis carinii pneumonia on human immunodeficiency virus disease progression
    Osmond, DH
    Chin, DP
    Glassroth, J
    Kvale, PA
    Wallace, JM
    Rosen, MJ
    Reichman, LB
    Poole, WK
    Hopewell, PC
    CLINICAL INFECTIOUS DISEASES, 1999, 29 (03) : 536 - 543
  • [25] Synthesis of tumor necrosis factor-alpha mRNA in bronchoalveolar lavage cells from human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia
    Rayment, N
    Miller, RF
    Ali, N
    Binks, MH
    Katz, DR
    JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (03): : 654 - 659
  • [26] Hypertrophic osteoarthropathy associated with Pneumocystis carinii pneumonia and human immunodeficiency virus infection
    Gunnarsson, G
    Karchmer, AW
    CLINICAL INFECTIOUS DISEASES, 1996, 22 (03) : 590 - 591
  • [27] Alveolar macrophages from human immunodeficiency virus-infected persons demonstrate impaired oxidative burst response to Pneumocystis carinii in vitro
    Koziel, H
    Li, XH
    Armstrong, MYK
    Richards, FF
    Rose, RM
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2000, 23 (04) : 452 - 459
  • [28] Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients:: A randomized trial by the CIOP Study group
    Mussini, C
    Pezzotti, P
    Antinori, A
    Borghi, V
    Monforte, AD
    Govoni, A
    De Luca, A
    Ammassari, A
    Mongiardo, N
    Cerri, MC
    Bedini, A
    Beltrami, C
    Ursitti, MA
    Bini, T
    Cossarizza, A
    Esposito, R
    CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) : 645 - 651
  • [29] Human immunodeficiency virus protease inhibitors and Pneumocystis carinii
    Atzori, C
    Cargnel, A
    JOURNAL OF INFECTIOUS DISEASES, 2002, 185 (11): : 1692 - 1693
  • [30] Permanent declines in pulmonary function following pneumonia in human immunodeficiency virus-infected persons
    Morris, AM
    Huang, L
    Bacchetti, P
    Turner, J
    Hopewell, PC
    Wallace, JM
    Kvale, PA
    Rosen, MJ
    Glassroth, J
    Reichman, LB
    Stansell, JD
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (02) : 612 - 616